share_log

Benchmark Maintains Speculative Buy on ImmunoPrecise Antibodies, Lowers Price Target to $3

Benzinga ·  Aug 15 01:32  · Ratings

Benchmark analyst Robert Wasserman maintains ImmunoPrecise Antibodies (NASDAQ:IPA) with a Speculative Buy and lowers the price target from $5 to $3.

The above content is for informational or educational purposes only and does not constitute any investment advice related to Futu. Although we strive to ensure the truthfulness, accuracy, and originality of all such content, we cannot guarantee it.
    Write a comment